Andrew Maleki
Vermogen: 19 533 $ op 30-09-2026
Vermogen: 19 533 $ op 30-09-2026
Andrew Maleki is Chief Financial Officer at Surrozen, Inc. since 2025.
Mr. Maleki was Head-Corporate Development at Lassen Therapeutics, Inc. from 2021 to 2025.
Mr. Maleki completed undergraduate studies at Yale University and earned an MBA from Harvard Business School.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
SURROZEN INC 0,01% | 15-06-2026 | 607 ( 0,01% ) | 19 533 $ | 30-09-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| SURROZEN, INC. | Financieel Directeur/CFO | 12-11-2025 |
| Bedrijven | Functie | Einde |
|---|---|---|
Lassen Therapeutics 1, Inc.
Lassen Therapeutics 1, Inc. BiotechnologyHealth Technology Develops novel and best-in-class biotherapeutics | Corporate Officer/Principal | 01-10-2025 |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 4 |
|---|---|
Yale University
Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Harvard Business School
Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Lassen Therapeutics 1, Inc.
Lassen Therapeutics 1, Inc. BiotechnologyHealth Technology Develops novel and best-in-class biotherapeutics | Health Technology |
Surrozen, Inc.
Surrozen, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that discovering and developing drug candidates | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau